NCM
JSPR icon

Nantahala Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Nantahala Capital Management’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-222,827
Closed -$1.76M – 135
2023
Q4 		$1.76M Sell
222,827
-17,463
-7% -$117K 0.11% 91
2023
Q3 		$1.68M Sell
240,290
-7,498
-3% -$91.5K 0.14% 94
2023
Q2 		$3.39M Buy
247,788
+78,943
+47% +$1.17M 0.33% 64
2023
Q1 		$3.06M Buy
+168,845
New +$3.12M 0.23% 66

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Nantahala Capital Management's JSPR Position: Q1 2024 in Review

Nantahala Capital Management sold out of Jasper Therapeutics (JSPR) in Q1 2024, closing a stake of 222,827 shares — an estimated $1.76M sold.

Nantahala Capital Management first reported a position in JSPR in Q1 2023 and held it in 4 quarters. The position peaked at $3.39M in Q2 2023. 61 funds tracked by Wall St. Rank hold JSPR as of Q1 2024.

  • Nantahala Capital Management reported no remaining Jasper Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Nantahala Capital Management sold 222,827 Jasper Therapeutics shares in Q1 2024, an estimated $1.76M.
  • Nantahala Capital Management first reported a position in Jasper Therapeutics in Q1 2023 and held it in 4 quarters.
  • Nantahala Capital Management's Jasper Therapeutics position peaked at $3.39M in Q2 2023.
  • 61 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2024.

Based on Nantahala Capital Management's 13F filing for Q1 2024, filed 15 May 2024.